Research Paper Volume 13, Issue 1 pp 437—449

Accumulation of LOX-1+ PMN-MDSCs in nasopharyngeal carcinoma survivors with chronic hepatitis B might permit immune tolerance to epstein–barr virus and relate to tumor recurrence

Mechanism of LOX-1+ PMN-MDSCs from NPC survivors with CHB and from patients with CHB. (A) Expression of SEC61A, sXBP1, ATF4, ATF6, ATF3, and CHOP in LOX-1+ PMN-MDSCs compared with LOX-1-PMN from the same donor were tested by RT-qPCR as well as NOX2 and ArgI, (n = 6). P*, Expression of genes in LOX-1+ PMN-MDSCs compared with LOX-1- PMN from the same donor. P#, Relative expression of genes in LOX-1+ PMN-MDSCs from NPC survivors with CHB compared with those from CHB patients. (B) Western blot analysis of expression of SEC61A, sXBP1, and CHOP proteins in LOX-1+ PMN-MDSCs compared with LOX-1- PMN among NPC survivors with CHB and patients with CHB. (C) ROS level illustrated by DCFDA in LOX-1+ PMN-MDSCs from NPC survivors with CHB and patients with CHB. LOX-1-PMN from these patients was used as a control. Left: Representative flow cytometry data (red, LOX-1-PMN; yellow, LOX-1+ PMN-MDSCs from patients with CHB; blue, LOX-1+ PMN-MDSCs from NPC survivors with CHB). Right: Cumulative data (n = 6 in each group). (D) Activity of arginase was tested in LOX-1+ PMN-MDSCs from NPC survivors with CHB and patients with CHB. LOX-1-PMN from these patients was used as a control (n = 6 in each group). Abbreviations: PMN-MDSC, polymorphonuclear myeloid-derived suppressor cell; NPC, nasopharyngeal carcinoma; CHB, chronic hepatitis B; CHOP, CCAAT/enhancer binding protein; PMN, polymorphonuclear cell; ROS, reactive oxygen species; DCFDA, 2′,7′-dichlorofluorescein diacetate.

Figure 3. Mechanism of LOX-1+ PMN-MDSCs from NPC survivors with CHB and from patients with CHB. (A) Expression of SEC61A, sXBP1, ATF4, ATF6, ATF3, and CHOP in LOX-1+ PMN-MDSCs compared with LOX-1-PMN from the same donor were tested by RT-qPCR as well as NOX2 and ArgI, (n = 6). P*, Expression of genes in LOX-1+ PMN-MDSCs compared with LOX-1- PMN from the same donor. P#, Relative expression of genes in LOX-1+ PMN-MDSCs from NPC survivors with CHB compared with those from CHB patients. (B) Western blot analysis of expression of SEC61A, sXBP1, and CHOP proteins in LOX-1+ PMN-MDSCs compared with LOX-1- PMN among NPC survivors with CHB and patients with CHB. (C) ROS level illustrated by DCFDA in LOX-1+ PMN-MDSCs from NPC survivors with CHB and patients with CHB. LOX-1-PMN from these patients was used as a control. Left: Representative flow cytometry data (red, LOX-1-PMN; yellow, LOX-1+ PMN-MDSCs from patients with CHB; blue, LOX-1+ PMN-MDSCs from NPC survivors with CHB). Right: Cumulative data (n = 6 in each group). (D) Activity of arginase was tested in LOX-1+ PMN-MDSCs from NPC survivors with CHB and patients with CHB. LOX-1-PMN from these patients was used as a control (n = 6 in each group). Abbreviations: PMN-MDSC, polymorphonuclear myeloid-derived suppressor cell; NPC, nasopharyngeal carcinoma; CHB, chronic hepatitis B; CHOP, CCAAT/enhancer binding protein; PMN, polymorphonuclear cell; ROS, reactive oxygen species; DCFDA, 2′,7′-dichlorofluorescein diacetate.